Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Carolus Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Macrophage migration inhibiting factor (MIF) has been a target for drug developers for years because of its potential to fight inflammation in a variety of indications. To date, efforts targeting MIF have been largely unsuccessful perhaps because, as Carolus Therapeutics' scientific founders theorized, MIF activity is mediated through two chemokine receptors, CXCR2 and CXCR4. Carolus has developed peptides that selectively disrupt MIF binding to those receptors, It also has a therapeutic antibodies program for MIF. If successful, its compunds could find application in a range of diseases, including cardiovascular disease, tissue transplant rejection, cancer, and a number of orphan indications

You may also be interested in...



Start-Up Previews (05/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Medical Dermatology Gets Under VCs' Skin," features profiles of Garnet Biotherapeutics, Medimetriks and Topica Pharmaceuticals. Plus these Start-Ups Across Health Care: Carolus Therapeutics, Forma Therapeutics, NovaLign Orthopaedics, OmegaGenesis and PercSys.

Homology Medicines Inc.

Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.

Topics

Related Companies

UsernamePublicRestriction

Register

SC091784

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel